SCHEMBL6505415

SCHEMBL6505415

O=C(O)N(S)Cc1cn(-c2ccc(N3CCOCC3)c(F)c2)nn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.45
HPGD P15428 3/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
RXRA P19793 3/20 0.43
GRIN1 Q05586 3/20 0.43
GRIN2B Q13224 3/20 0.43
MAOB P27338 6/20 0.42
IDO1 P14902 1/20 0.42
MAOA P21397 3/20 0.42
LMNA P02545 2/20 0.42
PTGS1 P23219 1/20 0.42
CALML3 P27482 1/20 0.42
SDHA P31040 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KDM1A O60341 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5624788 0.93 NPC1 (0.41) NPC1HPGDRAB9ASMN1; SMN2TP53
SCHEMBL6532331 0.86 MAOB (0.44) MAOBMAOALMNACYP1A2CYP3A4
SCHEMBL5622168 0.83 NOTUM (0.53) RXRAGRIN1GRIN2BKDM4EMAPT
SCHEMBL6505411 0.82 MAOB (0.48) NPC1HPGDRAB9ASMN1; SMN2TP53
SCHEMBL6926066 0.82 RXRA (0.41) RXRAGRIN1GRIN2BMAOBMAOA
SCHEMBL5622845 0.81 NOTUM (0.50) NPC1RXRAGRIN1GRIN2BMAOB
SCHEMBL5623214 0.81 MAOB (0.45) NPC1HPGDRAB9ASMN1; SMN2TP53
SCHEMBL14527061 0.80 MAOB (0.46) NPC1HPGDRAB9ASMN1; SMN2TP53
SCHEMBL5623649 0.80 NOTUM (0.57) NPC1HPGDRAB9ASMN1; SMN2RXRA
SCHEMBL5622486 0.80 NPC1 (0.46) NPC1HPGDRAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113347-A1 NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LIMITED 2005-05-26 US disclosed
EP-1467977-A1 NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. Dr. Reddy's Laboratories Ltd. (IN) 2004-10-20 EP disclosed
WO-2003059894-A1 NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. DR.REDDY'S LABORATORIES LTD. (IN) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113347-A1 NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP3A4, CYP3A43, CYP3A5 NPC1 1030/4885HPGD 2140/4885RAB9A 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.